A new official has been named to oversee the government’s massive infectious disease portfolio, the U.S. government announced Nov. 16.
Dr. John Powers, a physician and researcher, will direct the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) and oversee its annual budget of about $6.6 billion.
“Dr. Powers is a physician-scientist who has spent more than three decades caring for patients, teaching and mentoring the next generation of investigators, and playing an integral role in research that improves lives. He has been a trusted and valued colleague within NIAID for several decades, and will bring a focus on rigor, transparency, and research outcomes to leading the institute into the future,” Dr. Jay Bhattacharya, head of the NIH, who appointed Powers, said in a statement.
“I am thankful for his commitment to serve and glad to permanently welcome him to the NIH leadership team.”
Powers, who has a medical degree from the Temple University School of Medicine, has been with NIAID since 1999 and has been acting director of NIAID for several months. He was appointed after the agency’s previous leader, Dr. Jeffery Taubenberger, stepped down earlier in the year.
NIAID oversees research into infectious disease, allergies, and immunologic issues. It funds researchers across schools, institutions, and small businesses, and runs laboratories in Maryland and Montana.
Dr. David Morens, former adviser to the NIAID director, pleaded guilty in August to conspiring to defraud the United States by concealing records and is due to be sentenced in March 2027.
NIAID from 1984 through late 2022 was led by Dr. Anthony Fauci, who has not been charged with any crime despite a referral to federal prosecutors. During his tenure, it funded research that enhanced the pathogenic characteristics of pathogens, including research on bat coronaviruses at the laboratory in Wuhan, China, near where the first COVID-19 cases appeared. That type of testing is called gain-of-function research.
Bhattacharya has been critical of those efforts, and health officials, acting on an executive order from President Donald Trump, said in July they would not be providing federal funding for dangerous gain-of-function experiments.
Bhattacharya told the New York Post that Powers would make sure “we don’t conduct, you know, just bluntly, mad science experiments.”
He added, “No more dangerous gain of function will happen under John’s leadership.”
NIH leaders said earlier in the year that NIAID was being moved away from biodefense work to focus on diseases and conditions that are actually circulating among humans, including Ebola, as they attempt to restore trust in government health agencies.
“These priorities, in addition to the important ongoing and funded research portfolio, will collectively better prepare us for the future by driving basic, translational and clinical research that addresses the health challenges in immunological and infectious diseases that Americans face today,” Bhattacharya, Powers, and Taubenberger wrote in a paper in January.
Powers and Bhattacharya on Oct. 19 announced details of a new NIH center that would aim to treat people who developed health problems following vaccination, as well as potential long-COVID-19 cases. The vaccine injury center was announced on Oct. 8 by Health Secretary Robert F. Kennedy Jr.

